|
Take heed to this text  |
Supply: EndoQuest
EndoQuest Robotics Inc. and Omnivision have partnered to combine Omnivision’s CameraCubeChip into EndoQuest’s surgical robotic system.
Santa Clara, Calif.-based Omnivision develops semiconductor methods, together with superior digital imaging and contact show expertise.
Houston-based EndoQuest designed its system to deal with unmet wants in gastrointestinal and different endoluminal surgical procedures. The firm mentioned its proprietary expertise navigates inside the physique’s lumina areas such because the gut. This supplies the precision and adaptability for minimally invasive interventions, which might enhance affected person outcomes, it mentioned.
EndoQuest added that its platform permits therapeutic endoscopists and surgeons to function by way of a trans-oral or trans-anal strategy. Final month, the corporate raised $42 million. Final week, the U.S. Meals and Drug Administration’s Safer Applied sciences Program (STeP) accepted the surgical robotic system.
Omnivision to allow clearer surgical visualization
Omnivision designed the CameraCubeChip visualization system with its PureCel Plus-S pixel expertise.
PureCel Plus-S permits “excessive full-well capability, zero blooming and decrease energy consumption with crisp, clear, life-like photos,” mentioned Tehzeeb Gunja, director of medical advertising and marketing at Omnivision. He added that the compact, medical-grade providing may take affected person care and surgical visualization “to the following stage.”
“We’re excited to have the ability to incorporate Omnivision’s market-leading sensor expertise into the visualization element of our first-of-its-kind platform,” mentioned Kurt Azarbarzin, CEO of EndoQuest Robotics, in a launch. “We acknowledge that superior imaging is crucial to enhancing doctor capabilities, particularly contained in the lumen of the gastrointestinal (GI) tract. Omnivision’s latest expertise is good for our versatile robotic system.”
EndoQuest expects STeP to speed up entry
STeP supplies a streamlined growth and market evaluate course of for eligible medical units with the purpose of accelerating affected person entry with out compromising security and efficacy. The FDA launched STeP in 2021, modeling this system on its breakthrough units designation program.
STeP covers units that might enhance the security of therapies or diagnostics. They should be designed to deal with underlying ailments or circumstances thought-about much less critical than these handled or identified by units eligible for breakthrough designation.
“We consider that our distinctive robotic platform will improve doctor management, precision, and effectivity, enabling safer and simpler minimally invasive therapies,” acknowledged Azarbarzin. “We sit up for working with the FDA to deliver the Versatile Robotic System to market and supply physicians and sufferers a brand new, scar-free strategy for all kinds of medical circumstances and procedures.”
Editor’s be aware: This text was syndicated from MassDevice, a sibling website to The Robotic Report.